Scope
ACG treats eosinophilic oesophagitis as a chronic inflammatory disease requiring attention to both inflammation and fibrostenotic narrowing. Diagnosis combines symptoms, biopsies and evaluation of alternative causes; treatment and follow-up should assess symptoms, endoscopic findings and histology rather than symptoms alone.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish diagnosis and characterize disease
- Diagnose EoE when symptoms of oesophageal dysfunction accompany at least 15 eosinophils per high-power field on oesophageal biopsy, after evaluating other disorders that cause or contribute to oesophageal eosinophilia. This is a strong recommendation with low-quality evidence. [1]
- A failed PPI trial is no longer required to establish EoE: PPIs are a treatment option. Ask specifically about food avoidance and eating modifications, which can conceal dysphagia and delay diagnosis. [1]
- Use a systematic endoscopic score such as EREFS at every endoscopy. Obtain at least 6 oesophageal biopsies from at least 2 levels, targeting abnormal findings where possible, and quantify eosinophil counts on biopsies from every EoE endoscopy. [1]
Choose anti-inflammatory treatment jointly
- Use shared decision-making to choose dietary elimination or medication initially. When medication is chosen, the authors favour a single PPI or swallowed topical steroid because combination-treatment evidence is lacking; assess and treat fibrostenotic disease in parallel. [1]
- PPIs are a conditional treatment option for EoE, supported by low-quality evidence. Swallowed topical corticosteroids are strongly recommended with moderate-quality evidence; either fluticasone propionate or budesonide is conditionally suggested when a topical steroid is selected. [1]
- Counsel patients using swallowed topical corticosteroids about oral or oesophageal candidiasis. Routine adrenal-function testing is unnecessary for short courses, but consider it during continuous long-term use or use of multiple corticosteroid formulations. [1]
- An empiric food-elimination diet is a conditional option with low-quality evidence. A less restrictive starting diet is reasonable, with a more restrictive approach available according to patient preference; involve an EoE-experienced dietitian or nutritionist to optimize nutritional adequacy and feasibility. [1]
- Do not use currently available allergy testing to direct EoE food-elimination diets; this is a conditional recommendation with very-low-quality evidence. Such tests do not reliably identify the foods driving this disease. [1]
- For patients reintroducing previously avoided foods, or when loss of tolerance is a concern, seek allergy advice to determine whether reintroduction is safe at home or requires supervised oral food challenges. This safety role differs from using allergy tests to select an EoE elimination diet. [1]
Use biologics and procedures within their indications
- Dupilumab is conditionally suggested for EoE that has not responded to PPI therapy in people aged 12 or older, with moderate-quality evidence. It is also conditionally suggested in children aged 1–11 whose EoE has not responded to PPI therapy, with low-quality evidence; the source describes paediatric regulatory approval only for those weighing at least 15 kg. [1]
- In patients whose other atopic conditions independently meet indications for dupilumab, earlier use in the EoE treatment pathway may be considered in consultation with the relevant specialist. [1]
- The guideline makes no recommendation for or against cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab for EoE. It conditionally suggests against omalizumab, cromolyn and montelukast specifically as EoE treatments; these statements do not replace their separate indications for other conditions. [1]
- Consider endoscopic dilation as an adjunct to medical treatment for EoE strictures causing dysphagia. Pair dilation with anti-inflammatory treatment because dilation improves calibre and swallowing symptoms without treating the underlying inflammatory disease. [1]
Continue effective treatment and measure response
- Continue effective dietary or pharmacological therapy to prevent recurrence of symptoms, inflammation and endoscopic abnormalities. The recommendation is graded strong despite low-quality evidence; EoE requires ongoing treatment rather than stopping after initial improvement. [1]
- Assess treatment response using symptoms, endoscopic findings and histology together. Symptoms alone can improve despite ongoing inflammation after dilation or eating adaptations, or persist despite controlled inflammation because of strictures or other causes. [1]
- At response endoscopy, document EREFS and obtain oesophageal biopsies. A count below 15 eosinophils per high-power field is a reasonable histological goal for most patients, but interpret improvement relative to baseline and the other disease domains. [1]
- In general, assess a new PPI, swallowed topical steroid or elimination diet with endoscopy after 8–12 weeks. For dupilumab, the assessment may be at 12–24 weeks; adjust follow-up to the treatment and the individual patient. [1]
- Individualize follow-up, potentially at shorter intervals, after food impaction, perforation, strictures requiring dilation or malnutrition. If response is adequate, treatment stable and these complications absent, maintain regular clinical follow-up; after a treatment change such as dose reduction, repeat endoscopy to verify ongoing response. [1]
Address paediatric swallowing, nutrition and growth
- For a child with EoE and dysphagia, consider an oesophagram to assess fibrostenotic disease. This conditional recommendation has very-low-quality evidence; endoscopy can miss clinically important narrowing. [1]
- Consider feeding-therapist and/or dietitian assessment as an adjunct for children with EoE and feeding dysfunction. Track growth, eating-skill development and nutrient intake alongside symptom, endoscopic and histological improvement. [1]
- Ensure EoE is in remission before referral to a paediatric feeding programme: pain, reflux or dysphagia during meals can undermine the positive-reinforcement approach. Feeding assessment should include medical, nutritional, feeding-skill and psychosocial components. [1]
Limitations and use
- This selected summary covers the recommendation text and supporting clinical discussion. It does not reproduce all dosing tables, drug formulations, administration instructions or a complete dilation technique. Confirm formulation-specific age, weight, dose and local approval before prescribing. Diagnostic and treatment algorithms embedded as figures are not reproduced; the narrative recommendations are summarized.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis and Management of Eosinophilic Esophagitis (EoE)
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.